For instance, in a cohort of 3608 HER2-negative patients subjected to targeted NGS sequencing, Marra et al. found no difference in mutational signatures and tumor mutational burden overall and when cases were stratified by HR expression16. The gene discussed is ERBB2; the disease is neoplasm.